Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith the Proceedings of the 17th Annual General Meeting of the Company ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Sudarshan Pharma Industries Ltd held its 17th Annual General Meeting (AGM) on Friday, 25th July 2025 at 3:00 p.m. via Video Conferencing (VC) / Other Audio Visual Means. Chairman & Managing Director Mr. Hemal Mehta chaired the meeting, addressed members with an overview of current business, and outlined the company's expansion and growth strategy. The audited standalone and consolidated financial statements for FY ended 31st March 2025 were presented. Four resolutions were transacted: (1) Ordinary resolution to adopt the FY25 financial statements, (2) Ordinary resolution for the appointment of a director retiring by rotation (DIN 00432065), (3) Special resolution for the re-appointment of Hemal Mehta as Chairman & Managing Director, and (4) Special resolution appointing Mr. Vishal Manseta as Secretarial Auditor for FY 2025-26 to 2029-30. Mr. Vishal Manseta was also appointed as scrutinizer for the e-voting process. Voting results will be declared within 48 hours of AGM conclusion and shared with BSE and posted on the company website.
This is a routine regulatory disclosure confirming the AGM was conducted and resolutions were passed as planned. The re-appointment of the Chairman & Managing Director and the 5-year Secretarial Auditor appointment signal leadership continuity. No material impact on shareholders from the procedural completion itself; investors should await the voting results within 48 hours for confirmed outcomes.